As of 2025-01-13, the EV/EBITDA ratio of Cytosorbents Corp (CTSO) is -3.04. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CTSO's latest enterprise value is 59.53 mil USD. CTSO's TTM EBITDA according to its financial statements is -19.60 mil USD. Dividing these 2 quantities gives us the above CTSO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 19.2x - 21.7x | 20.8x |
| Forward P/E multiples | 21.3x - 23.4x | 21.5x |
| Fair Price | (7.75) - (7.92) | (7.72) |
| Upside | -926.9% - -944.5% | -922.9% |
| Date | EV/EBITDA |
| 2025-01-10 | -3.04 |
| 2025-01-08 | -3.13 |
| 2025-01-07 | -3.24 |
| 2025-01-06 | -3.32 |
| 2025-01-03 | -3.03 |
| 2025-01-02 | -2.99 |
| 2024-12-31 | -2.96 |
| 2024-12-30 | -2.93 |
| 2024-12-27 | -3.04 |
| 2024-12-26 | -2.93 |
| 2024-12-24 | -2.91 |
| 2024-12-23 | -2.76 |
| 2024-12-20 | -2.97 |
| 2024-12-19 | -2.88 |
| 2024-12-18 | -2.81 |
| 2024-12-17 | -2.68 |
| 2024-12-16 | -2.96 |
| 2024-12-13 | -3.24 |
| 2024-12-12 | -2.91 |
| 2024-12-11 | -2.88 |
| 2024-12-10 | -2.85 |
| 2024-12-09 | -2.88 |
| 2024-12-06 | -2.97 |
| 2024-12-05 | -3.00 |
| 2024-12-04 | -3.11 |
| 2024-12-03 | -3.07 |
| 2024-12-02 | -3.21 |
| 2024-11-29 | -3.13 |
| 2024-11-27 | -2.96 |
| 2024-11-26 | -2.93 |
| 2024-11-25 | -3.02 |
| 2024-11-22 | -2.99 |
| 2024-11-21 | -2.90 |
| 2024-11-20 | -2.98 |
| 2024-11-19 | -3.10 |
| 2024-11-18 | -3.02 |
| 2024-11-15 | -2.92 |
| 2024-11-14 | -3.07 |
| 2024-11-13 | -3.00 |
| 2024-11-12 | -3.13 |
| 2024-11-11 | -3.02 |
| 2024-11-08 | -2.48 |
| 2024-11-07 | -2.94 |
| 2024-11-06 | -2.99 |
| 2024-11-05 | -2.83 |
| 2024-11-04 | -2.85 |
| 2024-11-01 | -3.21 |
| 2024-10-31 | -3.24 |
| 2024-10-30 | -3.24 |
| 2024-10-29 | -3.27 |